RT Journal Article
SR Electronic
T1 Mini-XT, a miniaturized tagmentation-based protocol for efficient sequencing of SARS-CoV-2
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.29.21263685
DO 10.1101/2021.09.29.21263685
A1 Fuchs, Marc
A1 Radulescu, Clara
A1 Tang, Miao
A1 Mahesh, Arun
A1 Lavin, Deborah
A1 Umbreen, Syed
A1 McKenna, James
A1 Smyth, Mark
A1 McColgan, Eilís
A1 Molnar, Zoltan
A1 Baxter, Chris
A1 Skvortsov, Timofey
A1 Singh, Aditi
A1 Rogan, Fiona
A1 Miskelly, Julia
A1 Bridgett, Stephen
A1 Fairley, Derek
A1 Simpson, David A.
YR 2021
UL http://medrxiv.org/content/early/2021/10/01/2021.09.29.21263685.abstract
AB Introduction The COVID-19 pandemic has highlighted the importance of whole genome sequencing (WGS) of SARS-CoV-2 to inform public health policy. By enabling definition of lineages it facilitates tracking of the global spread of the virus. The evolution of new variants can be monitored and knowledge of specific mutations provides insights into the mechanisms through which the virus increases transmissibility or evades immunity. To date almost one million SARS-CoV-2 genomes have been sequenced by members of the COVID-19 Genomics UK (COG-UK) Consortium. To achieve similar feats in a more cost-effective and sustainable manner in future, improved high throughput virus sequencing protocols are required. We have therefore developed a miniaturized library preparation protocol with drastically reduced consumable use and costs.Methods SARS-CoV-2 RNA was amplified using the ARTIC nCov-2019 multiplex RT-PCR protocol and purified using a conventional liquid handling system. Acoustic liquid transfer (Echo 525) was employed to reduce reaction volumes and the number of tips required for a Nextera XT library preparation. Sequencing was performed on an Illumina MiSeq.Results We present the ‘Mini-XT’ miniaturized tagmentation-based library preparation protocol available on protocols.io (https://dx.doi.org/10.17504/protocols.io.bvntn5en). The final version of Mini-XT has been used to sequence 4,384 SARS-CoV-2 samples from N. Ireland with a COG-UK QC pass rate of 97.4%. Sequencing quality was comparable and lineage calling consistent for replicate samples processed with full volume Nextera DNA Flex (333 samples) or using nanopore technology (20 samples). SNP calling between Mini-XT and these technologies was consistent and sequences from replicate samples paired together in maximum likelihood phylogenetic trees.Conclusion The Mini-XT protocol maintains sequence quality while reducing library preparation reagent volumes 8-fold and halving overall tip usage from sample to sequence to provide concomitant cost savings relative to standard protocols. This will enable more efficient high-throughput sequencing of SARS-CoV-2 isolates and future pathogen WGS.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe sequencing costs were funded by the COVID-19 Genomics UK (COG-UK) Consortium which is supported by funding from the Medical Research Council (MRC) part of UK Research & Innovation (UKRI), the National Institute of Health Research (NIHR) and Genome Research Limited, operating as the Wellcome Sanger Institute. Additional funding was provided by Public Health England (PHE).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The COG-UK study protocol was approved by the Public Health England Research Ethics Governance Group. (Reference: R&D NR0195)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRoutine SARS-CoV-2 genome sequences determined in this study were deposited in the CLIMB database ( https://www.climb.ac.uk/) and are available for download along with all deposited sequences ( https://cog-uk.s3.climb.ac.uk/phylogenetics/latest/cog_all.fasta). Sequences generated in comparative studies are available upon request.